Literature DB >> 8889849

Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.

E Van Beek1, C Löwik, I Que, S Papapoulos.   

Abstract

The purpose of this study was to examine the role of the R1 moiety of bisphosphonates in binding to bone mineral and for antiresorptive action. For this, the R1 chain of three clinically useful hydroxybisphosphonates (etidronate, pamidronate, and olpadronate) was substituted with an amino group. The effects of the aminosubstituted bisphosphonates were compared with those of their hydroxy counterparts in a crystal growth assay and in fetal mouse long bone cultures which are representative of bisphosphonate actions in vivo. It was found that all three aminosubstituted compounds and their hydroxy analogs bound with similar affinity to bone mineral and inhibited the growth of calcium oxalate crystals to the same extent. Surprisingly, the antiresorptive effect of olpadronate was totally abolished by the amino substitution of the hydroxyl group while that of pamidronate was reduced by about six-fold and that of etidronate did not change. These studies demonstrate the involvement of the entire bisphosphonate molecule in the cellular mechanism of antiresorptive action. In addition, the aminosubstituted analog of olpadronate, which lacks any antiresorptive action but retains all other properties of olpadronate, provides an excellent tool for the study of specific cellular effects involved in bisphosphonate action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889849     DOI: 10.1002/jbmr.5650111016

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

1.  Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.

Authors:  Jivan N Yewle; David A Puleo; Leonidas G Bachas
Journal:  Bioconjug Chem       Date:  2011-12-05       Impact factor: 4.774

Review 2.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

3.  Treatment of glucocorticoid-induced osteoporsis.

Authors:  Gherardo Mazziotti; Andrea Giustina; Ernesto Canalis; John P Bilezikian
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-02       Impact factor: 5.346

Review 4.  Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants.

Authors:  Juan Pablo Cattalini; Aldo R Boccaccini; Silvia Lucangioli; Viviana Mouriño
Journal:  Tissue Eng Part B Rev       Date:  2012-05-14       Impact factor: 6.389

5.  1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase.

Authors:  Sergio H Szajnman; Valeria S Rosso; Leena Malayil; Alyssa Smith; Silvia N J Moreno; Roberto Docampo; Juan B Rodriguez
Journal:  Org Biomol Chem       Date:  2012-01-03       Impact factor: 3.876

6.  Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS).

Authors:  H Hirabayashi; T Sawamoto; J Fujisaki; Y Tokunaga; S Kimura; T Hata
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

Review 7.  Choosing a treatment for patients at the time a fracture is presented.

Authors:  S Bobo Tanner
Journal:  Curr Osteoporos Rep       Date:  2011-09       Impact factor: 5.096

8.  A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice.

Authors:  L I Plotkin; Nicoletta Bivi; T Bellido
Journal:  Bone       Date:  2010-08-22       Impact factor: 4.398

Review 9.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

Review 10.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.